Evaluating the safety of emicizumab in patients with hemophilia A

Arielle L. Langer(Brigham and Women's Hospital), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), Aaron Etra(Icahn School of Medicine at Mount Sinai)
Expert Opinion on Drug Safety
November 24, 2018
10.1080/14740338.2019.1551356
Cited by 18

Related Papers

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.
|PubMed|2001|803
Definitions in Hemophilia
|Thrombosis and Haemostasis|2001|772
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
|Journal of Internal Medicine|1994|613
A More Uniform Measurement of Factor VIII Inhibitors
|Thrombosis and Haemostasis|1975|587